论文部分内容阅读
目的：更准确地研究造血生长因子对骨髓增生异常综合征（ＭＤＳ）造血干、祖细胞的影响及临床治疗效果。方法：利用吸附单克隆抗体的免疫磁珠分离系统分离纯化ＭＤＳ患者ＣＤ３４＋细胞，在体外半固体培养体系中，研究ＭＤＳＣＤ３４＋细胞对粒－巨噬细胞集落刺激因子（ＧＭ－ＣＳＦ）、白细胞介素３（ＩＬ－３）、红细胞生成素（Ｅｐｏ）、干细胞因子（ＳＣＦ）单独及联合应用的反应。结果：ＭＤＳＣＤ３４＋细胞在增殖分化过程中存在一定程度缺陷，单独应用生长因子不能有效地改善其缺陷，ＳＣＦ与ＧＭ－ＣＳＦ、ＩＬ－３、Ｅｐｏ等生长因子的联合应用可提高一部分患者造血祖细胞的集落形成能力，但在ＭＤＳ高危组，部分患者在正常集落形成能力改善的同时，白血病细胞集落也有不同程度的增长。结论：治疗ＭＤＳ患者须合理地联合应用造血生长因子。
Objective: To study more accurately the effect of hematopoietic growth factor on hematopoietic stem and progenitor cells in patients with myelodysplastic syndrome (MDS) and the clinical therapeutic effect. Methods: CD34 + cells from MDS patients were isolated and purified by immunomagnetic bead adsorption system with monoclonal antibodies. The effects of MDSCD34 + cells on the proliferation of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), erythropoietin (Epo), and stem cell factor (SCF) alone and in combination. Results: The proliferation and differentiation of MDSCD34 + cells had some defects. The growth factor alone could not improve the defects of MDSCD34 + cells. The combination of SCF and GM-CSF, IL-3, Epo and other growth factors could increase the number of hematopoietic progenitor cells However, in the high-risk group of MDS, some patients showed an increase in normal colony-forming ability and leukemic cell colonies with different degrees of growth. Conclusion: Hematopoietic growth factors should be combined rationally in treatment of patients with MDS.